Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
28.45
+0.48 (1.70%)
as of Aug 25, 2026, 5:51:24 pm Market Open.
582 watching
Financials 
Technical Analysis 0
Investor Insights
Aug 25, 2026, 12:00 amThis summary was created by AI, based on 24 opinions in the last 12 months.
Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.
Consensus
Neutral
Valuation
Undervalued
Similar
MRK
BUY
The world seems to hate the large US phamaceuticals right now, but the valuation now is better than he has ever seen it. They generate good cash and can buy a bit of a pipeline if they have to.
John ZechnerOwned
biotechnologypharmaceutical
BUY
The largest pharmaceutical company in the world. Have a good pipeline of drugs. Well-managed.
Don ReedOwned
biotechnologypharmaceutical
TOP PICK
Owns this in tandem with Teva (TEVA-Q). This is their value company. Have had a lot of problems but feels this is already in the stock. Selling at about 10 or 11 X next year's earnings. Yield about 3.5%. Expect there will be an nice kick out of the stock when some of the problems are settled.
Norman LevineOwned
biotechnologypharmaceutical
BUY
The pharmaceutical area has been very difficult for a long time. They face an FDA which has been very difficult. Cheap from a historical point of view. Throw up tons of free cash flow. P/E is in the range of 10/12 X. It's a long road ahead for them. Thinks Pfizer's pipeline is being under valued. Bad news is already built into the stock.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Sept 7/05. Down 18%.) His model is still showing a 50% upside. Still likes.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
There are law suits coming at these companies from different directions. Merck (MRK-N) just got hit with a massive lawsuit in Texas and this has put a big pall over the industry. However, the demograpohics in this industry are fabulous. This one is the biggest in the industry and they have a huge amount of cash on their balance sheet. The options are very cheap and not a bad way to go.
biotechnologypharmaceutical
DON'T BUY
Not a fan of the big drug companies. They are under tremendous pressure. One of the biggest expenses the US has to grapple with is health care, so the government is now on the side of the consumer, so it would be very hard for big pharma to have the kind of margins and sales growth they used to have.
biotechnologypharmaceutical
BUY
The overall pharmaceutical industry has had a tough time. Yields almost 4%. Trading at close to 10 X earnings. This industry has had bad direction from the FDA. Great balance sheet and lots of free cash flow.
Paul Harris, CFAOwned
biotechnologypharmaceutical
WAIT
There's a possibility for it to go to $19.65 at which time he will buy more. It's in a bottoming process. Looking for the new earnings estimates to come in during the next few weeks. His model price is $36 which is a 51% differential.
Brian Acker, CAOwned
biotechnologypharmaceutical
BUY
Doesn't feel the FDA hasn't done a good job, but that is changing. Feels the pharmaceutical industry's pipeline is being valued at a very low multiple. At one of the cheapest levels in the last 10 years. Yields about 2.5/3%. Throws off tons of free cash flow. A long term story.
Paul Harris, CFAOwned
biotechnologypharmaceutical
DON'T BUY
Drug stars such as Pfizer (PFE-N) Merck (MRK-N), etc. are attractively valued but are clearly out of favour. They have great long term track records and are in strong financial positions, however, there is a lack of predictability regarding the science. Doesn't like the cash flow dynamics where they spend billions up front with no sure win ahead. Litigation risks.
James Cole, BA, CFAOwned
biotechnologypharmaceutical
BUY
Still likes and is a believer in this company. His model price is 50% above the current price, but doesn't know when that value will be recognized.
Brian Acker, CAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
